Gernot Riedel Selected Research

hydromethylthionine

4/2022	HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine.
1/2022	Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine.
1/2022	Glutamatergic transmission and receptor expression in the synucleinopathy h-α-synL62 mouse model: Effects of hydromethylthionine.
1/2021	Proteomic Analysis of Hydromethylthionine in the Line 66 Model of Frontotemporal Dementia Demonstrates Actions on Tau-Dependent and Tau-Independent Networks.
1/2020	Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
1/2019	Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
1/2018	Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.
1/2017	A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gernot Riedel Research Topics

Disease

19	Alzheimer Disease (Alzheimer's Disease) 04/2022 - 01/2005
8	Cognitive Dysfunction 04/2022 - 04/2002
8	Parkinson Disease (Parkinson's Disease) 01/2022 - 08/2008
5	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017 - 01/2005
4	Atrophy 04/2022 - 01/2018
4	Tauopathies 04/2022 - 01/2006
4	Dementia (Dementias) 01/2022 - 08/2009
4	Frontotemporal Dementia (Semantic Dementia) 01/2021 - 12/2015
4	Schizophrenia (Dementia Praecox) 01/2020 - 11/2015
3	Synucleinopathies 01/2022 - 01/2017
3	Memory Disorders (Memory Loss) 04/2010 - 12/2004
2	Inflammation (Inflammations) 01/2022 - 11/2015
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2021 - 08/2008
2	Mental Disorders (Mental Disorder) 01/2020 - 08/2011
2	Necrosis 03/2016 - 01/2016
2	Amnesia (Dissociative Amnesia) 04/2006 - 09/2002
1	Insulin Resistance 01/2021
1	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2020
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 01/2020
1	Anxiety Disorders (Anxiety Disorder) 01/2020
1	Bipolar Disorder (Manic Depressive Psychosis) 01/2020
1	Motor Disorders 01/2019
1	Gliosis 01/2018
1	Autoimmune Diseases (Autoimmune Disease) 01/2016
1	Fatty Liver 01/2016
1	Obesity 01/2016
1	Neuroinflammatory Diseases 01/2016
1	Glucose Intolerance 01/2016
1	Autism Spectrum Disorder 09/2014
1	Body Weight (Weight, Body) 08/2014
1	Constipation 02/2012
1	Rheumatic Diseases (Rheumatism) 02/2012
1	Malaria 02/2012
1	Vomiting 02/2012
1	Epilepsy (Aura) 08/2011
1	Sleep Wake Disorders 08/2011
1	Weight Gain 04/2009
1	Tetanus 12/2007
1	Shock 08/2002

Drug/Important Bio-Agent (IBA)

9	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2010
8	hydromethylthionineIBA 04/2022 - 01/2017
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2010
6	Cholinergic Agents (Cholinergics)IBA 01/2020 - 01/2006
3	tau Proteins (tau Protein)IBA 04/2022 - 12/2020
3	EnzymesIBA 01/2021 - 08/2014
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2016
3	Pharmaceutical PreparationsIBA 01/2020 - 04/2002
3	CannabinoidsIBA 01/2020 - 04/2010
3	EndocannabinoidsIBA 01/2020 - 04/2010
3	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 03/2016 - 11/2015
2	alpha-SynucleinIBA 01/2022 - 02/2018
2	Memantine (Namenda)FDA Link 01/2020 - 12/2007
2	SynucleinsIBA 01/2019 - 01/2017
2	Presenilin-1IBA 01/2018 - 01/2010
2	ParvalbuminsIBA 12/2017 - 11/2015
2	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 12/2015 - 01/2006
2	AM 251 (AM251)IBA 08/2014 - 04/2009
2	Peptides (Polypeptides)IBA 08/2014 - 01/2011
2	Dronabinol (THC)FDA LinkGeneric 04/2010 - 12/2004
2	CalciumIBA 08/2008 - 01/2005
2	N-Methylaspartate (NMDA)IBA 12/2007 - 01/2005
1	Rivastigmine (Exelon)FDA LinkGeneric 04/2022
1	Mesylates (Mesylate)IBA 01/2022
1	N- (3- (2- amino- 4a,5,7,7a- tetrahydro- 4H- furo(3,4- d)(1,3)thiazin- 7a- yl)- 4- fluorophenyl)- 5- fluoropicolinamideIBA 01/2021
1	Insulin ReceptorIBA 01/2021
1	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2020
1	Flavin-Adenine Dinucleotide (FAD)IBA 01/2018
1	InterferonsIBA 03/2016
1	Receptor for Advanced Glycation End ProductsIBA 01/2016
1	Neutralizing AntibodiesIBA 01/2016
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 01/2016
1	Liver GlycogenIBA 01/2016
1	HMGB1 Protein (HMG1)IBA 01/2016
1	Glycyrrhizic Acid (Glycyrrhizin)IBA 01/2016
1	Aripiprazole (Abilify)FDA Link 12/2015
1	Risperidone (Risperdal Consta)FDA LinkGeneric 12/2015
1	Olanzapine (Zyprexa)FDA Link 12/2015
1	Serotonin (5 Hydroxytryptamine)IBA 12/2015
1	Dopamine (Intropin)FDA LinkGeneric 12/2015
1	Kainic Acid Receptors (Kainate Receptor)IBA 09/2014
1	Biomarkers (Surrogate Marker)IBA 08/2011
1	anandamide (arachidonylethanolamide)IBA 04/2010
1	Cannabinoid Receptors (Cannabinoid Receptor)IBA 04/2009
1	Amyloid beta-PeptidesIBA 08/2008
1	Therapeutic UsesIBA 08/2008
1	Dihydrotachysterol (AT 10)IBA 12/2007
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 12/2007
1	Cholinergic Antagonists (Anticholinergics)IBA 04/2006
1	Amino Acids FDA Link 01/2005
1	HomocysteineIBA 01/2005
1	Glutamic Acid (Glutamate)FDA Link 01/2005
1	1-aminoindan-1,5-dicarboxylic acidIBA 09/2002

Therapy/Procedure

6	Therapeutics 04/2022 - 02/2012
1	Activities of Daily Living (ADL) 01/2018